| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.3 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.3 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |